山东医药
山東醫藥
산동의약
Shandong Medical Journal
2015年
39期
79-81
,共3页
痰热清注射液%全身炎症反应综合征%Meta分析
痰熱清註射液%全身炎癥反應綜閤徵%Meta分析
담열청주사액%전신염증반응종합정%Meta분석
Tanreqing injection%systemic inflammatory response syndrome%meta analysis
目的:系统评价痰热清注射液治疗全身炎症反应综合征的效果。方法检索Ovid/Pubmed、Embase、中国知网、万方数据知识服务平台、维普期刊资源整合服务平台、中国生物医学文献数据库,查找痰热清注射液治疗全身炎症反应综合征的随机对照试验(RCT),观察指标包括临床总有效率、WBC、血清C-反应蛋白(CRP)、TNF-α、血清降钙素原( PCT)、体温( T)。根据Jadad质量评分法对文献质量进行评价。结果最终纳入11篇文献,共811例患者,对照组396例、痰热清组415例。纳入文献质量总体不高,仅1篇为高质量文献。纳入文献存在发表偏倚。与对照组相比,痰热清组总有效率提高(OR=3.05,95%CI:1.46~6.39,P=0.003),WBC下降(WMD=1.39,95%CI:2.25~0.53,P=0.002),血清CRP(WMD=13.78,95%CI:19.96~7.60,P<0.0001)、PCT(SMD=2.17,95%CI:4.230.11,P=0.04)、TNF-α(SMD=-1.50,95%CI:2.14~0.85,P<0.00001)、IL-6(WMD=-24.04,95%CI:36.03~12.05,P<0.0001)降低,T降低(WMD=-0.66,95%CI:0.85~0.47,P<0.0001)。所有文献未报告痰热清注射液有不良反应。结论痰热清注射液治疗全身炎症反应综合征效果较好。
目的:繫統評價痰熱清註射液治療全身炎癥反應綜閤徵的效果。方法檢索Ovid/Pubmed、Embase、中國知網、萬方數據知識服務平檯、維普期刊資源整閤服務平檯、中國生物醫學文獻數據庫,查找痰熱清註射液治療全身炎癥反應綜閤徵的隨機對照試驗(RCT),觀察指標包括臨床總有效率、WBC、血清C-反應蛋白(CRP)、TNF-α、血清降鈣素原( PCT)、體溫( T)。根據Jadad質量評分法對文獻質量進行評價。結果最終納入11篇文獻,共811例患者,對照組396例、痰熱清組415例。納入文獻質量總體不高,僅1篇為高質量文獻。納入文獻存在髮錶偏倚。與對照組相比,痰熱清組總有效率提高(OR=3.05,95%CI:1.46~6.39,P=0.003),WBC下降(WMD=1.39,95%CI:2.25~0.53,P=0.002),血清CRP(WMD=13.78,95%CI:19.96~7.60,P<0.0001)、PCT(SMD=2.17,95%CI:4.230.11,P=0.04)、TNF-α(SMD=-1.50,95%CI:2.14~0.85,P<0.00001)、IL-6(WMD=-24.04,95%CI:36.03~12.05,P<0.0001)降低,T降低(WMD=-0.66,95%CI:0.85~0.47,P<0.0001)。所有文獻未報告痰熱清註射液有不良反應。結論痰熱清註射液治療全身炎癥反應綜閤徵效果較好。
목적:계통평개담열청주사액치료전신염증반응종합정적효과。방법검색Ovid/Pubmed、Embase、중국지망、만방수거지식복무평태、유보기간자원정합복무평태、중국생물의학문헌수거고,사조담열청주사액치료전신염증반응종합정적수궤대조시험(RCT),관찰지표포괄림상총유효솔、WBC、혈청C-반응단백(CRP)、TNF-α、혈청강개소원( PCT)、체온( T)。근거Jadad질량평분법대문헌질량진행평개。결과최종납입11편문헌,공811례환자,대조조396례、담열청조415례。납입문헌질량총체불고,부1편위고질량문헌。납입문헌존재발표편의。여대조조상비,담열청조총유효솔제고(OR=3.05,95%CI:1.46~6.39,P=0.003),WBC하강(WMD=1.39,95%CI:2.25~0.53,P=0.002),혈청CRP(WMD=13.78,95%CI:19.96~7.60,P<0.0001)、PCT(SMD=2.17,95%CI:4.230.11,P=0.04)、TNF-α(SMD=-1.50,95%CI:2.14~0.85,P<0.00001)、IL-6(WMD=-24.04,95%CI:36.03~12.05,P<0.0001)강저,T강저(WMD=-0.66,95%CI:0.85~0.47,P<0.0001)。소유문헌미보고담열청주사액유불량반응。결론담열청주사액치료전신염증반응종합정효과교호。
Objective To evaluate the efficacy of Tanreqing injection in treatment of systemic inflammatory response syndrome (SIRS) systematically.Methods We retrieved Ovid/Pubmed, Embase, CNKI, Wanfang data, VIP and Chi-nese biomedical literature database to search for the randomized controlled trial ( RCT) of Tanreqing injection in the treat-ment of SIRS , and then we observed the following indexes , including the clinical total effective rate , white blood cell count (WBC), serum C-reactive protein (CRP) and serum tumor necrosis factor-α(TNF-α), serum calcitonin (PCT) and tem-perature ( T) .According to the Jadad quality evaluation , we evaluated the literatures .Results Eleven trials were eligible finally, and contained 811 cases of patients including 396 patients treated with conventional treatment and 415 with Tan-reqing injection based on conventional treatment , only one literature was of high-quality.Meta analysis showed that the therapeutic effect of SIRS treated with Tanreqing injection was better than that treated by routine alone , and it reflected mainly in the following:the total clinical efficiency was increased (OR=3.05, 95%CI:1.46-6.39, P=0.003), the level of WBC (WMD=1.39,95%CI:2.25 to 0.53, P=0.002), the level of CRP (WMD=13.78, 95%CI:19.96 to 7.60, P<0.00 01), the level of PCT (SMD=2.17, 95%CI:4.23 to 0.11, P=0.04), the level of TNF-α(SMD=-1.50, 95%CI:2.14 to 0.85, P<0.00 001), and the level of IL-6 (WMD=-24.04,95%CI:36.03 to 12.05, P<0.00 01) were decreased, ant the level of T was decreased (WMD=-0.66, 95%CI:0.85 to 0.47, P<0.00 01).No serious adverse reactions were reported .Conclusion Tanreqing injection has good effect in treatment of SIRS .